| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 北京北陆药业股份有限公司是一家主要从事药品生产以及药品经销的公司,其中药品生产包括对比剂系列产品、降糖类药物和抗焦虑类中药等产品的生产及销售.对比剂系列产品为公司的主导产品,主要包括磁共振对比剂钆喷酸葡胺注射液、非离子型碘对比剂碘海醇注射液和口服磁共振对比剂枸橼酸铁铵泡腾颗粒.公司是我国对比剂行业的市场领先者,2010年公司注射剂所有产品共计11个规格均通过国家SFDA再注册.公司的研发项目分别获得国家和北京市的扶持与资助,"九味镇心颗粒制剂项目"入选2010年北京市火炬计划产品,公司还被评选为中关村科技园首批"百家创新型试点企业"、"北京生物医药产业跨越发展工程"(G20工程)企业。 | ||||||||||||||||||||||||
| Main Business | 对比剂系列产品、降糖类药物和抗焦虑类中药等药品的研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | WANG XU | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 邵泽慧 | ||||||||||||||||||||||||
| Solicitors | 北京市浩天信和律师事务所 | ||||||||||||||||||||||||
| Auditors | 致同会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 010－62625287 | ||||||||||||||||||||||||
| Fax No | 010－82626933 | ||||||||||||||||||||||||
| Website | www.beilu.com.cn | ||||||||||||||||||||||||
| blxp@beilu.com.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 30/10/2009 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ -0.150 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 3.126 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 3.222B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |